Feature | Heart Valve Technology | October 16, 2015

Study Shows Definitive Neuro Benefit to Using TAVR Embolic Protection

Sentinel device shown to protect the vast majority of brain regions from risk of cerebral infarcts; reduces number and volume of brain lesions by more than 50 percent

Claret embolic protection, TAVR, cerebral protection

The Claret TAVR embolic protection system as seen in the aortic arch under angiography. The loops contain embolic filters they protect the ostium of vessles leading to the brain.

Claret embolic protection, TAVR, cerebral protection

October 14, 2015 — Claret Medical, an innovator in cardiovascular cerebral protection, Data presented this week at Transcatheter Cardiovascular Therapeutics (TCT) 2015 showed the first definitive cognitive benefit from use of a cardiovascular cerebral protection system during transcatheter aortic valve replacement (TAVR) procedures. 

Data from the MISTRAL-C study show that patients who received a Claret Medical Sentinel Cerebral Protection System (CPS) during TAVR faired better than unprotected patients. Unprotected patients had a statistically significant (p=0.017) worsening in cognition when compared to Sentinel-protected patients at five days post-TAVR, when assessed using the Mini Mental State Exam (MMSE).

MISTRAL-C also validates findings from the landmark CLEAN-TAVI study that showed the use of a Claret Medical cerebral protection system reduced the number and volume of brain lesions in TAVR patients.[1] MISTRAL-C showed a 52 percent reduction in the median total new lesion volume at five days post-procedure as assessed using highly sensitive 3.0 Tesla brain MRI.  None of the protected patients had National Institute of Health Stroke Scale (NIHSS) deterioration at five days post-procedure, while 5 percent of unprotected patients showed deterioration.
 
MISTRAL-C studied 65 patients enrolled at four centers in the Netherlands that underwent TAVR using both self-expanding and balloon-expandable valves, with and without the use of the Sentinel CPS. The study compared the median total new lesion volume as detected by DW-MRI at five days post-procedure to pre-procedural baseline cerebral scans. It also included a detailed neurological and cognitive assessment of patients five days post-procedure.
 
“What is clear in MISTRAL-C is that patients not protected by the Sentinel CPS showed significant cognitive decline post-procedure when compared to those protected by the Sentinel CPS.  Protected patients also showed a robust reduction in the number and volume of new cerebral lesions at five days,” said Principal Investigator Nicholas van Mieghem, M.D., Thoraxcenter, Erasmus Medical Center, Rotterdam.

 Also presented at TCT was a post hoc, 3-D voxel-wise analysis of CLEAN-TAVI DW-MRI images illustrating that only two percent of the left posterior region of the brain remains fully unprotected when a Claret Medical cerebral protection system is used. The data were presented by Axel Linke, M.D., professor of medicine, Department of Internal Medicine/Cardiology, University of Leipzig, Germany.
 
“Post-hoc neuroimaging and neurological analysis is providing a more complete, and troubling, picture of the brain post-TAVR,” Linke said. “Evidence is building that more sustained damage than we previously realized may be created when we don’t protect the brain from embolic debris. The use of cerebral protection, however, has now been shown to effectively shield the brain from potentially dangerous debris showers caused by the TAVR procedure.”
 
Claret Medical Chief Executive Officer Azin Parhizgar, Ph.D., said by incorporation of 3.0T MRI analysis at baseline in clinical studies, CLEAN-TAVI showed nearly 40 percent of patients present with pre-existing lesions, and 17 percent of those with volume greater than 100 mm.[2] Utilizing the more sensitive 3.0T MRI enables an accurate way to quantify the number and volume of all new lesions caused by TAVR.
 
The Sentinel CPS received the CE mark in 2013 and now, more than 2,000 commercial cases have been performed using Claret Medical’s cerebral protection technology. The Sentinel CPS is also currently being studied in the United States and Europe as part of the SENTINEL pivotal trial, the first FDA-approved trial of a cerebral protection system and the largest randomized trial in the field to date. 
 
For more information: www.claretmedical.com
 
References:  
1.     Linke A. “CLEAN-TAVI: A Prospective, Randomized Trial of Cerebral Embolic Protection in High Risk Patients with Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement.” Transcatheter Cardiovascular Therapeutics (TCT). 2014

2.     van Mieghem N et al. “Histopathology of Embolic Debris Captured During Transcatheter Aortic Valve Replacement.” Circulation. 2013;127:2194-2201

Related Content

transradial approach, same-day cardiac procedures, radial access, $300 million annual savings, JACC Cardiovascular Interventions study
News | Radial Access| February 22, 2017
If hospitals can perform more transradial, same-day percutaneous coronary intervention (PCI), hospitals across the U.S...
Edwards Intuity Elite sutureless aortic valve, first implants in Connecticut, WCHN, Western Connecticut Health Network
News | Cardiovascular Surgery| February 16, 2017
Western Connecticut Health Network (WCHN) cardiothoracic surgeons Cary Passik, M.D., and Robert Gallagher, M.D., were...
Cardinal Health survey, hospital staff, supply chain management, quality of care
News | Inventory Management| February 15, 2017
Better hospital supply chain management leads to better quality of care and supports patient safety, according to a new...
University of Alabama at Birmingham, Amplatzer PFO Occluder, first implementation
News | Structural Heart Occluders| February 15, 2017
Doctors at the University of Alabama at Birmingham have implemented the first U.S. Food and Drug Administration (FDA)-...
heart team, hybird OR, structural heart team

The heart team approach was first used on a large scale in the CoreValve and Sapien TAVR trials and helped lead to excellent outcomes in high-risk patients.

Feature | Hybrid OR| February 15, 2017 | Dave Fornell
In the current era of healthcare reform and the push toward evidence-based medicine to both lower costs and improve p
 Intra-atrial shunt device (IASD) to lower left atrial pressure by creating a small left atrial to right atrial shunt.  Abraham said these devices are in early stage development with small studies to show proof of concept and demonstrate safety.

The Corvia Intra-atrial shunt device (IASD) lowers left atrial pressure by creating a small left atrial to right atrial shunt. Preliminary clinical studies have shown promise for these types of devices to improve HFpEF patient outcomes.

Feature | Heart Failure| February 10, 2017 | Dave Fornell
In the past few years there have been a number of device therapies developed to treat heart failure (HF).
Sponsored Content | Videos | Heart Failure| February 06, 2017
This video demonstrates how to implant the Revivent TC System to reduce the volume of the left ventricle (LV) in hear
Amplatzer PFO Occluder, St. Jude Medical, Baylor Heart and Vascular Services, Fort Worth, Texas, first patients
News | Structural Heart Occluders| February 01, 2017
Baylor Heart and Vascular Services at Fort Worth in November became the first program in Texas to implant the Amplatzer...
Edwards Lifesciences, completes acquisition, Valtech Cardio
News | Heart Valve Technology| January 25, 2017
Edwards Lifesciences Corp. announced that it has closed its acquisition of Valtech Cardio Ltd., developer of the...
SAVR, surgical aortic valve replacement, elderly patients, aortic stenosis, Society of Thoracic Surgeons, clinical study
News | Structural Heart| January 25, 2017
Elderly patients with aortic stenosis (AS) and medium surgical risk experienced better than expected results after...
Overlay Init